A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia


We are delighted to share with you that REMAP-CAP has been selected by the NIHR as the 
platform trial to evaluate therapeutic interventions for influenza! It is great that they have recognised all the fantastic work you have helped achieve with COVID-19 and now we can continue to use our exciting trial design to study flu in a wider population. 

What is this study about?

REMAP-CAP is an international (15 countries) adaptive platform trial in community acquired pneumonia, that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients. In addition to recruiting patients with community acquired pneumonia who have been admitted to critical care, we are also recruiting patients with COVID-19 to understand optimal treatment strategies.

The trial is modular so that new domains (groups of similar treatment options) can be added over time.

The website for REMAP-CAP has now moved to

Please use the above link for all REMAP-CAP information.

Privacy Notice:-

Copyright © 2024 ICNARC